Liminal BioSciences Inc. [LMNL] Stock trading around $6.29 per share: What’s Next?

Liminal BioSciences Inc. [NASDAQ: LMNL] traded at a high on 02/18/21, posting a 9.58 gain after which it closed the day’ session at $6.29. The company report on February 16, 2021 that NorthShore® Adult Diapers Announces Expansion Into Canada.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Leading U.S. brand for heavy incontinence protection now stocked locally in Canada by two leading direct-to-consumer internet retailers.

– NorthShore Care Supply, the company behind NorthShore®, the leading brand of high-absorbency adult diapers and incontinence supplies, recently announced its expansion into Canada. NorthShore has served customers in the U.S. for nearly two decades, focused on providing products to people of all ages managing moderate to heavy incontinence with up to 3x the leak protection of leading store brands.

The results of the trading session contributed to over 2428300 shares changing hands. Over the past one week, the price volatility of Liminal BioSciences Inc. stands at 10.25% while the volatility over the past one month is 9.07%.

The market cap for LMNL stock reached $183.23 million, with 23.59 million shares outstanding and 9.50 million shares in the current float. Compared to the average trading volume of 1.47M shares, LMNL reached a trading volume of 2428300 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Liminal BioSciences Inc. [LMNL]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LMNL shares is $9.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LMNL stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Liminal BioSciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 18, 2021. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on December 21, 2020, representing the official price target for Liminal BioSciences Inc. stock.

The Average True Range (ATR) for Liminal BioSciences Inc. is set at 0.56, with the Price to Sales ratio for LMNL stock in the period of the last 12 months amounting to 70.47. The Price to Book ratio for the last quarter was 5.24, with the Price to Cash per share for the same quarter was set at 0.97.

How has LMNL stock performed recently?

Liminal BioSciences Inc. [LMNL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.18. With this latest performance, LMNL shares gained by 12.52% in over the last four-week period, additionally sinking by -60.04% over the last 6 months – not to mention a drop of -33.37% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LMNL stock in for the last two-week period is set at 64.21, with the RSI for the last a single of trading hit 67.15, and the three-weeks RSI is set at 60.93 for Liminal BioSciences Inc. [LMNL]. The present Moving Average for the last 50 days of trading for this stock 4.86, while it was recorded at 5.93 for the last single week of trading, and 8.77 for the last 200 days.

Liminal BioSciences Inc. [LMNL]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Liminal BioSciences Inc. [LMNL] shares currently have an operating margin of -2423.08 and a Gross Margin at -136.97. Liminal BioSciences Inc.’s Net Margin is presently recorded at -4754.89.

Return on Total Capital for LMNL is now -114.82, given the latest momentum, and Return on Invested Capital for the company is -223.53. Return on Equity for this stock declined to -940.75, with Return on Assets sitting at -173.43. When it comes to the capital structure of this company, Liminal BioSciences Inc. [LMNL] has a Total Debt to Total Equity ratio set at 46.06. Additionally, LMNL Total Debt to Total Capital is recorded at 31.54, with Total Debt to Total Assets ending up at 28.51. Long-Term Debt to Equity for the company is recorded at 37.79, with the Long-Term Debt to Total Capital now at 25.87.

Reflecting on the efficiency of the workforce at the company, Liminal BioSciences Inc. [LMNL] managed to generate an average of -$585,777 per employee. Receivables Turnover for the company is 0.30 with a Total Asset Turnover recorded at a value of 0.04.Liminal BioSciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 2.20.

Insider trade positions for Liminal BioSciences Inc. [LMNL]

There are presently around $4 million, or 6.80% of LMNL stock, in the hands of institutional investors. The top three institutional holders of LMNL stocks are: ARMISTICE CAPITAL, LLC with ownership of 565,242, which is approximately New of the company’s market cap and around 67.67% of the total institutional ownership; SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC, holding 68,415 shares of the stock with an approximate value of $0.43 million in LMNL stocks shares; and ATOM INVESTORS LP, currently with $95000.0 in LMNL stock with ownership of nearly -71.489% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Liminal BioSciences Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 7 institutional holders increased their position in Liminal BioSciences Inc. [NASDAQ:LMNL] by around 675,833 shares. Additionally, 7 investors decreased positions by around 3,139,876 shares, while 3 investors held positions by with 3,116,983 shares. The mentioned changes placed institutional holdings at 698,726 shares, according to the latest SEC report filing. LMNL stock had 6 new institutional investments in for a total of 674,149 shares, while 2 institutional investors sold positions of 3,097,920 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam